1. Introduction
===============

Alzheimer's disease was first recognized by Alois Alzheimer as presenile dementia in 1906. It is mainly diagnosed in people whose ages are over 65 with the prevalence of Alzheimer's Disease (AD) being shown to grow exponentially with age. It is prevalent among 10% of elderly people, which makes AD an emerging social health issue with the rise of an aging population in the coming decades. Specially, at the age of 85, 50% of the people face the risk of developing AD \[[@B1-ijms-15-12631],[@B2-ijms-15-12631]\]. However, AD is not exactly an aging-related disease \[[@B3-ijms-15-12631]\]. In fact, it has been classified into two types. One is the gene-related heritable AD, known as the early onset familial Alzheimer's disease (fAD). The clinical symptoms can appear in a very young age and it accounts for 25% of all AD cases \[[@B4-ijms-15-12631]\]. Another type is the sporadic Alzheimer's disease (sAD), which constitutes the vast majority of AD cases and is also apparently influenced by genetic contributions besides non-genetic environmental factors \[[@B5-ijms-15-12631],[@B6-ijms-15-12631],[@B7-ijms-15-12631]\]. Several genes have been identified to increase the chance of developing fAD and sAD. However, the pathological role of the only identified *є*4 *lipoprotein E* (APOE) gene in sAD is still unclear. In addition, the mutation of APOE *є*4 is not necessary to increase the risk of developing sAD \[[@B8-ijms-15-12631],[@B9-ijms-15-12631]\]. Thus, the late-onset AD degenerative process has been speculated to be polygenic with the involvement of multiple risk factors \[[@B6-ijms-15-12631]\].

It is well known that the early symptoms of AD include loss of short-term memory, difficulties in executing daily life activities, and withdrawal from social life. The behavioral symptoms include progressive decline in memory, spatial reasoning, attention, and languages. AD is mainly characterized by two pathological hallmarks: the intracellular neurofibrillary tangle (NFT) formed by hyperphosphorylated tau proteins, and the extracellular amyloid plaque consisting of amyloid *β* peptides. Significant selective neuronal degeneration and loss, with neurotransmitter deficits and inflammations are also evident \[[@B10-ijms-15-12631]\]. In the following section, we first delve into the root of AD by giving a short review on genetic risk factors. After which, we shall discuss on two focal areas of current AD research. One involves the intracellular accumulation of tau protein while the other is on extracellular amyloid aggregation. The former is covered in [Section 3](#sec3-ijms-15-12631){ref-type="sec"} and the latter is addressed in [Section 4](#sec4-ijms-15-12631){ref-type="sec"}, [Section 5](#sec5-ijms-15-12631){ref-type="sec"} and [Section 6](#sec6-ijms-15-12631){ref-type="sec"}. In [Section 7](#sec7-ijms-15-12631){ref-type="sec"}, we connect these two aspects of AD research to provide a panoramic view of the generative mechanism of AD. We briefly discuss on the progression pathway of AD and the possible therapeutic approaches in [Section 8](#sec8-ijms-15-12631){ref-type="sec"}. Finally, we conclude our review in [Section 9](#sec9-ijms-15-12631){ref-type="sec"}.

2. Genetic Revelation of AD
===========================

With the higher level of gene expression in the brain, the cumulative DNA damage may have a cascading effect on the transcriptional effectivity and fidelity, and the alteration of DNA conformation in the hippocampus region has been observed in the brain of AD patients \[[@B11-ijms-15-12631],[@B12-ijms-15-12631]\]. For the two types of Alzheimer's---early onset (a.k.s. familial AD) and later onset (a.k.s. sporadic AD), both have a genetic connection. Familial AD involves a number of single-gene mutations on chromosomes 1, 14 and 21, which corresponds to the abnormal presenilin 2, presenilin 1 and amyloid precursor protein production respectively \[[@B13-ijms-15-12631],[@B14-ijms-15-12631],[@B15-ijms-15-12631],[@B16-ijms-15-12631],[@B17-ijms-15-12631]\], and each of these mutations is believed to play a very important role in the cleavage of APP and thus affect A*β* production. The late-onset AD accounts for the major cases of AD, notwithstanding a lack of full understanding, the genetic risk factors, such as the definitively identified *apolipoprotein E* (*APOE*) gene on chromosome 19 \[[@B18-ijms-15-12631]\] and the *methylenetetrahydrofolate dehydrogenase 1-like* (*MTHFD1L*) gene on chromosome 6 \[[@B19-ijms-15-12631]\] as well as some other loci \[[@B20-ijms-15-12631],[@B21-ijms-15-12631],[@B22-ijms-15-12631],[@B23-ijms-15-12631]\], are likely to affect the predisposition of AD. Additionally, the genome-wide study of AD cases also revealed new novel variants, which may modify the age of the AD onset or show gender-linked susceptibility \[[@B24-ijms-15-12631],[@B25-ijms-15-12631]\].

3. Tau Protein and Tau Accumulation {#sec3-ijms-15-12631}
===================================

Tau protein arises from the alternative splicing of the *microtubule-associated protein tau* (*MAPT*) gene, and is abundant within the central and peripheral nervous systems. It is one of the intrinsically unstructured proteins (IUPs), which exhibit as random coils under physiological conditions, and are capable of folding into well-defined stable structures, e.g., the neurofibrillary tangles in AD. Normally, it is the phosphorylation-modified tau protein that stabilizes the axonal microtubules in the central nervous system (CNS). Moreover, tau protein with actin cytoskeleton and plasma membrane serve as enzyme anchors, and they are also believed to help in the neurite outgrowth and the transport of axoplasm. However, under certain circumstances, tau protein may undergo abnormal phoshorylation, hyperphosphorylation and some other modifications -nitration, ubiquitination, truncation, shift, prolyl isomerization, which may reduce the binding affinity of tau towards microtube, and thus lead to either intraneuronal accumulation of tau protein or its binding to other macromolecules \[[@B26-ijms-15-12631],[@B27-ijms-15-12631],[@B28-ijms-15-12631],[@B29-ijms-15-12631]\].

The mislocalization and accumulation of tau proteins in dendrites and dendritic spines brings about a disruption of neuronal cell communication, which precedes neurodegeneration and causes a loss of memory \[[@B30-ijms-15-12631]\]. Tau self-assemblies of tau proteins forming straight filaments (SFs) and/or paired helical filaments (PHF) may further aggregate into NFT, which is significantly correlated with the severity of AD. Electron microscopy of PHFs showed the appearance of two strands twisting around each other with a cross-over repeat of 75--80 nm and a width of 10--22 nm \[[@B31-ijms-15-12631],[@B32-ijms-15-12631]\]. It has also been further revealed that *β*-sheet is the most dominant structure in the PHFs.

4. Amyloid Plaque and A*β* Peptide {#sec4-ijms-15-12631}
==================================

4.1. Amyloid Precursor Protein
------------------------------

The amyloid *β* plaques results from the aggregation of the amyloid *β* (A*β*) peptides, which is cleaved by the *β*-and γ-secreastase from the amyloid precursor protein (APP). The precise biological function of APP is as yet not well defined even though lots of studies have revealed its biological and physiological importance in the neurite outgrowth modulation \[[@B33-ijms-15-12631]\], copper homeostasis regulation \[[@B34-ijms-15-12631]\], synaptic transmission and formation, and synaptic function and activity \[[@B35-ijms-15-12631],[@B36-ijms-15-12631]\]. On the other hand, it has been shown that the absence of APP in a mouse model did not cause a significant impairment of cognitive abilities, but instead led to a decrease in locomotion activity \[[@B37-ijms-15-12631]\].

4.2. A*β* Aggregation Pathway
-----------------------------

Neuronal impairment is observed in patients even before A*β* plaque formation during the early onset AD. It is generally believed that A*β* oligomer is the main culprit of neurotoxicity \[[@B38-ijms-15-12631],[@B39-ijms-15-12631],[@B40-ijms-15-12631],[@B41-ijms-15-12631]\]. Due to these oligomers being easily attached to the membrane or other macromolecules and hard to be isolated from these structures, conventional experimental studies on them are very difficult \[[@B42-ijms-15-12631]\]. A progress has been made recently which shows that A*β* dimers can be measured and strongly associated with dementia \[[@B43-ijms-15-12631]\]. Besides the experimental methods, molecular dynamic simulation is a complementary approach for atomic-level studies of the unstructured monomer aggregation process, structural evolution and toxicity.

4.3. Structural Evolution during Aggregation
--------------------------------------------

In recent decades, Nuclear Magnetic Resonance (NMR) and X-ray have been carried out to determine the structures of A*β* in water and membrane mimic environment (see [Table 1](#ijms-15-12631-t001){ref-type="table"}). One general observation is that A*β* peptides exhibit great polymorphism.

ijms-15-12631-t001_Table 1

###### 

Structural data of amyloid beta peptide obtained from experiments.

  PDB ID                          Experimental Technique   Resolution   Release Date   Residue   DOI
  ------------------------------- ------------------------ ------------ -------------- --------- ------------------------------
  1AMB \[[@B44-ijms-15-12631]\]   SOLUTION NMR             \-           1994-12-20     1--28     \-
  1AMC \[[@B44-ijms-15-12631]\]   SOLUTION NMR             \-           1995-01-26     1--28     \-
  1AML \[[@B45-ijms-15-12631]\]   SOLUTION NMR             \-           1996-01-29     1--40     \-
  1BA4 \[[@B46-ijms-15-12631]\]   SOLUTION NMR             \-           1998-06-17     1--40     \-
  1BA6 \[[@B47-ijms-15-12631]\]   SOLUTION NMR             \-           1998-06-17     1--40     10.1021/bi972979f
  1BJB \[[@B48-ijms-15-12631]\]   SOLUTION NMR             \-           1998-11-04     1--28     10.1006/jsbi.2000.4267
  1BJC \[[@B48-ijms-15-12631]\]   SOLUTION NMR             \-           1998-11-18     1--28     10.1006/jsbi.2000.4267
  1HZ3 \[[@B49-ijms-15-12631]\]   SOLUTION NMR             \-           2001-01-31     1--26     10.1002/pro.5560060902
  1IYT \[[@B50-ijms-15-12631]\]   SOLUTION NMR             \-           2003-02-11     1--42     10.1006/jsbi.2000.4288
  1NMJ \[[@B51-ijms-15-12631]\]   SOLUTION NMR             \-           2003-01-28     1--28     10.1038/7562
  1QWP \[[@B52-ijms-15-12631]\]   SOLUTION NMR             \-           1997-07-07     25--35    10.1021/bi961598j
  1QXC \[[@B52-ijms-15-12631]\]   SOLUTION NMR             \-           2004-09-14     25--35    \-
  1QYT \[[@B52-ijms-15-12631]\]   SOLUTION NMR             \-           2004-12-14     25--35    10.1021/jm040773o
  1ZE7 \[[@B53-ijms-15-12631]\]   SOLUTION NMR             \-           2005-05-03     1--16     10.1074/jbc.M504454200
  2BP4 \[[@B53-ijms-15-12631]\]   SOLUTION NMR             \-           2005-04-21     1--16     10.1074/jbc.M504454200
  2LI9 \[[@B54-ijms-15-12631]\]   SOLUTION NMR             \-           2011-07-20     1--16     10.1016/j.bbrc.2011.06.133
  2LI9 \[[@B54-ijms-15-12631]\]   SOLUTION NMR             \-           2012-01-18     1--16     \-
  2M9S \[[@B55-ijms-15-12631]\]   SOLUTION NMR             \-           \-             1--40     10.1016/j.bbagen.2013.06.031
  2Y2A \[[@B56-ijms-15-12631]\]   X-RAY DIFFRACTION        \-           2011-10-26     16--21    10.1073/pnas.1112600108
  2Y3J \[[@B56-ijms-15-12631]\]   X-RAY DIFFRACTION        1.91         \-             30--35    10.1073/pnas.1112600108
  2Y3L \[[@B56-ijms-15-12631]\]   X-RAY DIFFRACTION        2.1          2011-11-02     35--42    10.1073/pnas.1112600108
  2Y3K \[[@B56-ijms-15-12631]\]   X-RAY DIFFRACTION        2.1          2011-11-02     35--42    10.1073/pnas.1112600108
  3Q2X \[[@B56-ijms-15-12631]\]   X-RAY DIFFRACTION        2.1          2011-11-02     27--32    10.1073/pnas.1112600108
  3PZZ \[[@B56-ijms-15-12631]\]   X-RAY DIFFRACTION        2.1          2011-11-02     29--34    10.1073/pnas.1112600108
  3OVJ \[[@B57-ijms-15-12631]\]   X-RAY DIFFRACTION        1.8          2011-07-06     16--21    10.1016/j.molcel.2004.06.037
  3OW9 \[[@B56-ijms-15-12631]\]   X-RAY DIFFRACTION        1.8          2011-08-31     16--21    10.1371/journal.pbio.1001080
                                  SOLUTION NMR             \-           2004-09-14     25--35    10.1021/jm040773o
                                  SOLUTION NMR             \-           2012-01-18     1--16     10.1016/j.bpj.2011.11.4006
  2OTK \[[@B58-ijms-15-12631]\]   3D NMR                   \-           2013-09-11     1--40     10.1016/j.bbagen.2013.06.031

In many situations, A*β* is found to easily attach to other protein, or self-assemble into large oligomers or fibrils. These complex involving A*β* peptides, such as APP, A*β* binding copper ions, A*β* segments with enzymes as observed in experiment, are cataloged in [Table 2](#ijms-15-12631-t002){ref-type="table"}.

ijms-15-12631-t002_Table 2

###### 

Experimental data of amyloid beta oligomers, fibrills and binding proteins.

  PDB ID                           Experimental Technique   Resolution   Release Date   Residues Count   DOI
  -------------------------------- ------------------------ ------------ -------------- ---------------- --------------------------------
  1AAP \[[@B59-ijms-15-12631]\]    X-RAY DIFFRACTION        1.5          1991-10-15     116              \-
  1BRC \[[@B60-ijms-15-12631]\]    X-RAY DIFFRACTION        2.5          1994-05-31     279              10.1006/jmbi.1993.1211
  1TAW \[[@B61-ijms-15-12631]\]    X-RAY DIFFRACTION        1.8          1997-06-24     281              10.1002/pro.5560060902
  1CA0 \[[@B61-ijms-15-12631]\]    X-RAY DIFFRACTION        2.1          1997-07-23     590              10.1002/pro.5560060902
  1X11 \[[@B62-ijms-15-12631]\]    X-RAY DIFFRACTION        2.5          1998-01-14     370              10.1093/emboj/16.20.6141
  1MWP \[[@B63-ijms-15-12631]\]    X-RAY DIFFRACTION        1.8          2000-03-15     96               10.1038/7562
  1OQN \[[@B64-ijms-15-12631]\]    X-RAY DIFFRACTION        2.3          2003-08-05     336              10.1074/jbc.M304384200
  1OWT \[[@B65-ijms-15-12631]\]    SOLUTION NMR             \-           2003-05-13     66               10.1074/jbc.M300629200
  1TKN \[[@B66-ijms-15-12631]\]    SOLUTION NMR             \-           2004-08-03     110              10.1021/bi049041o
  1ZJD \[[@B67-ijms-15-12631]\]    X-RAY DIFFRACTION        2.6          2005-08-09     294              10.1074/jbc.M504990200
  2BEG \[[@B68-ijms-15-12631]\]    SOLUTION NMR             \-           2005-11-22     210              10.1073/pnas.0506723102
  2G47 \[[@B69-ijms-15-12631]\]    X-RAY DIFFRACTION        2.1          2006-10-24     2060             10.1038/nature05143
  2FJZ \[[@B70-ijms-15-12631]\]    X-RAY DIFFRACTION        1.61         2007-01-16     59               10.1016/j.jmb.2006.12.041
  2FK1 \[[@B70-ijms-15-12631]\]    X-RAY DIFFRACTION        1.6          2007-01-16     59               10.1016/j.jmb.2006.12.041
  2FK2 \[[@B70-ijms-15-12631]\]    X-RAY DIFFRACTION        1.65         2007-01-16     59               10.1016/j.jmb.2006.12.041
  2FK3 \[[@B70-ijms-15-12631]\]    X-RAY DIFFRACTION        2.4          2007-01-16     472              10.1016/j.jmb.2006.12.041
  2FKL \[[@B70-ijms-15-12631]\]    X-RAY DIFFRACTION        2.5          2007-01-16     132              10.1016/j.jmb.2006.12.041
  2FMA \[[@B71-ijms-15-12631]\]    X-RAY DIFFRACTION        0.85         2007-01-16     59               10.1107/S1744309107041139
  2IPU \[[@B72-ijms-15-12631]\]    X-RAY DIFFRACTION        1.65         2007-10-09     906              10.1073/pnas.0705888104
  2R0W \[[@B72-ijms-15-12631]\]    X-RAY DIFFRACTION        2.5          2007-10-16     450              10.1073/pnas.0705888104
  2OTK \[[@B58-ijms-15-12631]\]    SOLUTION NMR             \-           2008-02-12     182              10.1073/pnas.0711731105
  2ROZ \[[@B73-ijms-15-12631]\]    SOLUTION NMR             \-           2008-07-22     168              10.1074/jbc.M803892200
  3BAE \[[@B74-ijms-15-12631]\]    X-RAY DIFFRACTION        1.59         2008-04-15     474              10.1016/j.jmb.2007.12.036
  3BKJ \[[@B74-ijms-15-12631]\]    X-RAY DIFFRACTION        1.59         2008-04-15     492              10.1016/j.jmb.2007.12.036
  3DXC \[[@B75-ijms-15-12631]\]    X-RAY DIFFRACTION        2.1          2008-09-16     350              10.1038/embor.2008.188
  3DXD \[[@B75-ijms-15-12631]\]    X-RAY DIFFRACTION        2.2          2008-09-16     350              10.1038/embor.2008.188
  3DXE \[[@B75-ijms-15-12631]\]    X-RAY DIFFRACTION        2.0          2008-09-16     350              10.1038/embor.2008.188
  3GCI \[[@B76-ijms-15-12631]\]    X-RAY DIFFRACTION        2.04         2009-03-10     126              \-
  3IFL \[[@B77-ijms-15-12631]\]    X-RAY DIFFRACTION        1.5          2009-11-17     448              10.1074/jbc.M109.045187
  3IFN \[[@B77-ijms-15-12631]\]    X-RAY DIFFRACTION        1.5          2009-11-17     481              10.1074/jbc.M109.045187
  3IFO \[[@B77-ijms-15-12631]\]    X-RAY DIFFRACTION        2.15         2009-11-17     904              10.1074/jbc.M109.045187
  3IFP \[[@B77-ijms-15-12631]\]    X-RAY DIFFRACTION        2.95         2009-11-17     1808             10.1074/jbc.M109.045187
  3JQ5 \[[@B76-ijms-15-12631]\]    X-RAY DIFFRACTION        2.03         2009-09-29     127              \-
  3JQL \[[@B76-ijms-15-12631]\]    X-RAY DIFFRACTION        1.2          2009-09-29     125              \-
  2WK3 \[[@B78-ijms-15-12631]\]    X-RAY DIFFRACTION        2.59         2009-11-03     2122             10.1016/j.jmb.2009.10.072
  3KTM \[[@B79-ijms-15-12631]\]    X-RAY DIFFRACTION        2.7          2010-02-23     1528             10.1073/pnas.0911326107
  3L81 \[[@B80-ijms-15-12631]\]    X-RAY DIFFRACTION        1.6          2010-06-02     308              10.1016/j.devcel.2010.01.015
  3JTI \[[@B81-ijms-15-12631]\]    X-RAY DIFFRACTION        1.8          2010-07-21     127              \-
  3L33 \[[@B82-ijms-15-12631]\]    X-RAY DIFFRACTION        2.48         2010-09-22     1104             10.1074/jbc.M110.171348
  3MOQ \[[@B83-ijms-15-12631]\]    X-RAY DIFFRACTION        2.05         2011-02-16     504              10.1523/JNEUROSCI.4259-10.2011
  3MXC \[[@B84-ijms-15-12631]\]    X-RAY DIFFRACTION        2.0          2011-05-11     110              10.1016/j.jmb.2011.09.046
  3NYJ \[[@B85-ijms-15-12631]\]    X-RAY DIFFRACTION        3.2          2011-06-01     207              10.1021/bi101846x
  3NYL \[[@B86-ijms-15-12631]\]    X-RAY DIFFRACTION        2.8          2011-07-13     210              10.1016/j.molcel.2004.06.037
  2Y3J \[[@B87-ijms-15-12631]\]    X-RAY DIFFRACTION        1.99         2011-11-02     48               10.1073/pnas.1112600108
  2Y3K \[[@B87-ijms-15-12631]\]    X-RAY DIFFRACTION        1.9          2011-11-02     64               10.1073/pnas.1112600108
  3AYU \[[@B88-ijms-15-12631]\]    X-RAY DIFFRACTION        2.0          2011-08-03     177              10.1074/jbc.M111.264176
  2LMN \[[@B89-ijms-15-12631]\]    SOLID-STATE NMR          \-           2011-12-28     480              10.1021/bi051952q
  2LMO \[[@B89-ijms-15-12631]\]    SOLID-STATE NMR          \-           2011-12-28     480              10.1021/bi051952q
  2LMP \[[@B90-ijms-15-12631]\]    SOLID-STATE NMR          \-           2011-12-28     720              10.1073/pnas.0806270105
  2LMQ \[[@B90-ijms-15-12631]\]    SOLID-STATE NMR          \-           2011-12-28     720              10.1073/pnas.0806270105
  2LNQ \[[@B91-ijms-15-12631]\]    SOLID-STATE NMR          \-           2012-02-08     320              10.1073/pnas.1111305109
  2LOH \[[@B92-ijms-15-12631]\]    SOLUTION NMR             \-           2012-05-23     86               10.1016/j.febslet.2012.04.062
  2LP1 \[[@B93-ijms-15-12631]\]    SOLUTION NMR             \-           2012-06-06     122              10.1126/science.1219988
  2LLM \[[@B94-ijms-15-12631]\]    SOLUTION NMR             \-           2012-06-20     43               PMCID: PMC3347594
  3U0T \[[@B95-ijms-15-12631]\]    X-RAY DIFFRACTION        2.5          2012-01-11     894              10.1016/j.jmb.2011.11.047
  3UMH \[[@B96-ijms-15-12631]\]    X-RAY DIFFRACTION        2.0          2012-01-25     211              10.1016/j.jmb.2011.12.057
  3UMI \[[@B96-ijms-15-12631]\]    X-RAY DIFFRACTION        2.4          2012-01-25     211              10.1016/j.jmb.2011.12.057
  3UMK \[[@B96-ijms-15-12631]\]    X-RAY DIFFRACTION        2.6          2012-01-25     211              10.1016/j.jmb.2011.12.057
  3SV1 \[[@B97-ijms-15-12631]\]    X-RAY DIFFRACTION        3.3          2012-07-11     612              10.1093/jmcb/mjs033
  4HIX \[[@B98-ijms-15-12631]\]    X-RAY DIFFRACTION        2.2          2013-03-13     475              10.1038/srep01302
  2M4J \[[@B99-ijms-15-12631]\]    SOLUTION NMR             \-           2013-09-25     360              10.1016/j.cell.2013.08.035
  2LZ3 \[[@B100-ijms-15-12631]\]   SOLUTION NMR             \-           2013-10-02     56               \-
  2LZ4 \[[@B100-ijms-15-12631]\]   SOLUTION NMR             \-           2013-10-02     56               \-

The central amyloidogenic step of the oligomerization process is the transition from *α*-helix rich (starting from the conformation of APP before being cleavaged) to *β*-sheet rich structures. All atom simulation of A*β*~37−42~ reveals the polymorphism of A*β* oligomers \[[@B101-ijms-15-12631]\]. Replica exchange molecular dynamics simulations were conducted to study the short peptide A*β*~10−35~ \[[@B102-ijms-15-12631]\] and A*β*~16−22~ \[[@B103-ijms-15-12631]\] dimer and trimer formations as well as the A*β*~16−35~ monomer and dimer structure and thermodynamics properties \[[@B104-ijms-15-12631]\]. A coarse-grained model of A*β*~1−42~ was used to study the structural diversity of the dimer \[[@B105-ijms-15-12631]\] in aqueous environment. A single A*β*~40~ peptide was used to study its structural diversity \[[@B106-ijms-15-12631]\] and the relevant effects of insertion depth and ionic strength in the DPPC membrane environment \[[@B107-ijms-15-12631]\]. Further study shows that the thermodynamics and dynamics of A*β* oligomerization are sequence dependent \[[@B108-ijms-15-12631]\].

A*β* has two alloforms: one is A*β*~1−40~, the other is A*β*~1−42~. Both have distinct effects and pathways during oligomerization \[[@B109-ijms-15-12631],[@B110-ijms-15-12631]\]. It is generally believed that A*β*~1−40~ peptides are non-amyloidogentic while A*β*~1−42~ are amyloidogentic. Recent studies have shown that A*β* peptides produced in the area with elevated level of cholesterol pose a great risk of Alzheimer's disease \[[@B111-ijms-15-12631]\] and those genes associated with the cholesterol regulation play a significant role in the predisposition of AD. Here, it raises the question on the effect of cholesterol binding to A*β* peptide and the associated mechanisms of A*β* aggregation in the membrane environment. Recent studies done by our group show that cholesterol molecules compete with the intra-action of A*β* oligomers by binding directly with A*β* peptides. This implies that monomeric A*β* and/or small A*β* aggregations prefer to locate within cholesterol-rich membranes \[[@B111-ijms-15-12631],[@B112-ijms-15-12631],[@B113-ijms-15-12631]\]. Furthermore, A*β* structure evolution in the presence of small and macro-molecules, such as curcumin \[[@B114-ijms-15-12631],[@B115-ijms-15-12631]\], heme \[[@B116-ijms-15-12631]\], resveratrol \[[@B115-ijms-15-12631],[@B117-ijms-15-12631]\], mitoxantrone and pixantrone \[[@B118-ijms-15-12631]\], derivatives of Congo Red \[[@B119-ijms-15-12631]\], 1,4-naphthoquinon-2-yl-L-tryptophan inhibitor \[[@B120-ijms-15-12631]\], EGCG \[[@B115-ijms-15-12631],[@B121-ijms-15-12631]\], NqTrp \[[@B115-ijms-15-12631]\], and inflammation protein complex \[[@B122-ijms-15-12631]\], are also studied. In these studies, A*β* aggregation behaviour is found to be either inhibited or promoted.

The single mutation of A*β* are also performed to study the mutation effect on A*β* oligomerization process. A2V mutation in A*β*~1−28~ shows that the intrinsic disorder are reduced with a completely different free energy landscape \[[@B123-ijms-15-12631]\]. D7N mutation on the A*β*~40~ and A*β*~42~ exhibits a notable change in secondary structure, final topology and salt bridge compared with wild type \[[@B124-ijms-15-12631]\]. D23N mutation also causes a distinct dimerization pathways compared with wild type in A*β*~1−42~ and A*β*~1−40~ \[[@B110-ijms-15-12631]\].

The detailed fibril nucleation and oligomerization are further probed from kinetics and thermodynamics aspect via computational method \[[@B125-ijms-15-12631]\].

5. Amyloid Fibril Formation and Polymorphism {#sec5-ijms-15-12631}
============================================

Since the end of the 20th century, much effort has been made to understand the structure of amyloid fibrils and the mechanism of its formation. With the development of measurement techniques, such as NMR and X-ray crystallography, the polymorphic structures of amyloid fibril have been revealed. The main contribution to the distinct structures of the fibril is the sensitivity of the fibril growth towards the surrounding conditions \[[@B126-ijms-15-12631],[@B127-ijms-15-12631],[@B128-ijms-15-12631]\]. Despite the multiple differences in their overall structures, there exists a common a well-characterized antiparallel *β*-sheets within the fibrils \[[@B127-ijms-15-12631]\]. Molecular dynamics simulations have been employed to investigate the detailed mechanisms of the A*β* fibril formation by adding monomers into the structured oligomers \[[@B129-ijms-15-12631]\]. It was found that the incorporation of the monomers into the oligomers occurs in two distinct stages: the first stage is a rapid conformational change of the monomers from a disordered structure to one with a significant amount of beta-strand content. The second stage is a relatively slow process, namely the docking of the monomer which has adjusted itself into a well-registered antiparallel structure.

6. A*β* Isoforms --- Variants of A*β* {#sec6-ijms-15-12631}
=====================================

The amyloid-cascade hypothesis holds a stronghold in the research of AD. It posits that the process of A*β* aggregation into oligomers and final deposition as plaques is the central pathological events in AD. As stated earlier, A*β*~40~ and A*β*~42~ are two well-recognized isoforms of A*β* being produced. Meanwhile, with the conduct of intensive research in this area, several *C*-terminal truncated isoforms, such as A*β*~43~ \[[@B130-ijms-15-12631],[@B131-ijms-15-12631]\], A*β*~1−15/16~ \[[@B132-ijms-15-12631]\], and carboxyterminally truncated A*β* peptides 1 − 37/38/39 \[[@B133-ijms-15-12631]\], have been revealed and they are suggested to play a crucial role in the AD pathogenesis. In particular, experimental data obtained from both sporadic and familial AD shows that A*β*~43~ is more prevalent than A*β*~40~ in plaque core \[[@B130-ijms-15-12631]\].

Interestingly, in AD brains there are a significant proportion of *N*-terminal truncated A*β* variants, such as A*β*~2−17~,A*β*~3−17~ \[[@B134-ijms-15-12631]\], A*β*~*n*−40/42~ with *n* ranges from 2 to 11 \[[@B135-ijms-15-12631]\], pyroglutamate-modified amyloid beta (A*β*~3(*pE*)−42~) and A*β*~11(*pE*)−42~ peptides \[[@B136-ijms-15-12631]\]. Among them the pyroglutamate-modified amyloid beta appears to be the predominant components \[[@B137-ijms-15-12631],[@B138-ijms-15-12631],[@B139-ijms-15-12631]\]. The earliest report of the pyroglutamate-modified amyloid beta-peptides dates back to 1997 and earlier \[[@B140-ijms-15-12631],[@B141-ijms-15-12631]\]. After a decade of inactivity following 1997 and only within the recent five years have some researchers begun to understand their formation \[[@B142-ijms-15-12631]\], structure \[[@B143-ijms-15-12631]\], oligomerization \[[@B144-ijms-15-12631]\], intracellular accumulation \[[@B145-ijms-15-12631]\], and its potential as therapeutic target \[[@B138-ijms-15-12631]\]. At the same time, the first reported peptide in A*β* plaque, the A*β*~4−42~ peptide, has received no attention even though it is as toxic as pyroglutamate-modified amyloid beta peptides and A*β*~42~ \[[@B135-ijms-15-12631]\].

7. A*β* Oligomers and Tau Protein: Relationship and Link {#sec7-ijms-15-12631}
========================================================

There are various means by which A*β* oligomers are distributed among cells. These are: diffusion or spread within extracellular parenchymas as oligomers or deposited plaques; adsorption on membrane surface or incorporation into membrane structure forming pores or channels; and accumulation within the neuronal structure. On the other hand, the tau protein is mainly distributed within the intracellular neuron. One possible direct link between the intraneuronal A*β* and tau protein involves the modulation effect between A*β* and tau pathologies \[[@B146-ijms-15-12631]\].

Studies have shown that intracellular accumulation appears earlier than amyloid plaque and NFT, and have suggested that intraneuronal A*β* accumulation initiates the caspase-cleavage of tau and precedes the A*β* plaque and NFT formation \[[@B147-ijms-15-12631],[@B148-ijms-15-12631]\]. Meanwhile, tau hyperphosphorylation signal transduction pathways may also be linked indirectly to A*β* oligomers. Recent reviews on the relationship between A*β* pathway and tau pathology can be accessed from references \[[@B146-ijms-15-12631],[@B149-ijms-15-12631]\].

8. AD Progression Pathway and Current Therapeutic Strategies {#sec8-ijms-15-12631}
============================================================

Mild cognitive impairment (MCI) has been used to prescribe the transitional stage between healthy brain and dementia. One impairment subtype is amnesic mild cognitive impairment (aMCI), which may increase the risk of progression to AD. Due to a variation in definitions of MCI based on different clinical criteria, the pathology of aMCI still lacks a strong characteristic profile. In terms of the intermediate stages towards AD, MCI shares a lot of similarity with AD, *i.e.*, an increase of NFT in the medial temporal lobe (namely, hippocampus) amygdala.

In the last few years, donepezil, rivastigmine, and galantamine are prescribed drugs for AD patients to target acetylcholinesterase that inhibits the breaking down of acetylcholine. Another drug memantine has been used to block glutamate receptors against excitotoxicity as a means to cure AD. To date, the acetylcholinesterase inhibitors are the most widely used AD drug and have been to some extent successful in slowing down the process of cognitive impairment \[[@B150-ijms-15-12631]\].

9. Conclusions {#sec9-ijms-15-12631}
==============

Alzheimer's disease is a complex and progressive neuro-degenerative disease. There are numerous studies from different points of view on the pathology of AD, such as those mentioned in this review, which involve genetic and environmental factors, tau protein and neurofibrillary tangles, the variety of its isoforms as well as amyloid beta peptides and oligomers. However, all of these issues are not isolated. In all likelihood, the actions among extracellular amyloid *β* peptides and intracellular tau proteins are closely related to each other through a series of complicated, but essentially important, processes and events. Despite the strong links between A*β* and tau protein that have been reported so far, a panorama study of these deeply connected roadmap is still missing. In order to explore the whole landscape of AD, a step by step strategy is of paramount importance, such as the uncovering of the mechanism of A*β* peptide aggregation, which will help to decipher the whole story on the pathogenesis of AD.
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